My research focuses on addressing the critical challenges posed by the tumour microenvironment, which plays a pivotal role in cancer progression, immune evasion, and therapeutic resistance. I am working on developing novel strategies to target the tumour microenvironment with the aim of improving treatment outcomes. Translational science lies at the core of these efforts, bridging the gap between laboratory discoveries and clinical applications. By leveraging human-derived samples, including primary ascites and freshly resected solid biopsies, I have developed several advanced preclinical models to validate therapeutic approaches in clinically relevant settings. My research integrates bioinformatics, immunotherapy, and oncolytic virotherapy to create more effective treatments for solid cancers. This includes engineering bispecific antibodies to remodel the immunosuppressive tumour microenvironment. These efforts aim to accelerate the transition of promising therapies from the bench to the bedside.